Lianxin Liu

liulx@ustc.edu.cn

Chinese, English

Anhui

University of Science and Technology of China

Mayo Clinic College of Medicine

• 1988.09-1993.07 Bachelor: Harbin Medical University
• 1995.09-1997.07 Master: Harbin Medical University
• 1997.09-2000.07 Doctorate: Harbin Medical University
• Chief Scientist of the Ministry of Science and Technology's Major Project on 'Transformative Technology'
• Changjiang Scholar Distinguished Professor by the Ministry of Education
• National High-Level Talent Special Support Program for Scientific and Technological Innovation Leading Talent
• Recipient of the State Council Special Allowance
• First foreign fellow of the American College of Surgeons (FACS) in Anhui

• 2000.07-2001.10 - Harbin Medical University, First Affiliated Hospital - Lecturer
• 2001.11-2003.08 - Harbin Medical University, First Affiliated Hospital - Associate Professor, Associate Chief Physician
• 2003.09-2018.10 - Harbin Medical University, First Affiliated Hospital - Professor, Chief Physician
• 2018.11-present - University of Science and Technology of China, First Affiliated Hospital - Professor, Chief Physician

• Chief Scientist of the Ministry of Science and Technology's Major Project on 'Transformative Technology' (2020.6)
• State Council Special Allowance (2020.12)
• National Health and Wellness Outstanding Contribution Young and Middle-aged Expert (2021.3)
• Jianghuai Famous Doctor (2021.11)
• Anhui Provincial Excellent Graduate Supervisor Team (2022.12)

Diagnosis and treatment of common and frequently occurring diseases in general surgery
Research on the relationship between inflammation, metabolism, non-coding RNA, immunity, viruses, and hepatobiliary tumors
Research on the pathogenesis, metastasis, recurrence, and drug resistance reversal mechanisms of hepatobiliary tumors
Research on minimally invasive treatment, comprehensive treatment, immunotherapy, and organ transplantation related to hepatobiliary tumors

• Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy, Liu Y, Xun Z, Ma K, Liang S, Li X, Zhou S, Sun L, Liu Y, Du Y, Guo X, Cui T, Zhou H, Wang J, Yin D, Song R, Zhang S, Cai W, Meng F, Guo H, Zhang B, Yang D, Bao R, Hu Q, Wang J, Ye Y, Liu L, 2023
• The diapause-like colorectal cancer cells induced by SMC4 attenuation are characterized by low proliferation and chemotherapy insensitivity, Sun X, He L, Liu H, Thorne RF, Zeng T, Liu L, Zhang B, He M, Huang Y, Li M, Gao E, Ma M, Cheng C, Meng F, Lang C, Li H, Xiong W, Pan S, Ren D, Dang B, Yang Y, Wu M, Liu L, 2023
• Donafenib and GSK-J4 Synergistically Induce Ferroptosis in Liver Cancer by Upregulating HMOX1 Expression, Zheng C, Zhang B, Li Y, Liu K, Wei W, Liang S, Guo H, Ma K, Liu Y, Wang J, Liu L, 2023
• Targeting SLP2-mediated lipid metabolism reprograming restricts proliferation and metastasis of hepatocellular carcinoma and promotes sensitivity to Lenvatinib, Liu Y, Sun L, Guo H, Zhou S, Wang C, Ji C, Meng F, Liang S, Zhang B, Yuan Y, Ma K, Li X, Guo X, Cui T, Zhang N, Wang J, Liu Y, Liu L, 2023
• UBE2O reduces the effectiveness of interferon-α via degradation of IFIT3 in hepatocellular carcinoma, Li H, Liu Y, Cheng C, Wu Y, Liang SH, Wu L, Wang H, Tu CY, Yao HH, Meng FZ, Zhang B, Wang W, Wang JB, Liu LX, 2023
• Mitochondrial SENP2 regulates the assembly of SDH complex under metabolic stress, Liu Y, Liu K, Thorne RF, Shi R, Zhang Q, Wu M, Liu L, 2023
• LncRNA NEAT1 suppresses cellular senescence in hepatocellular carcinoma via KIF11-dependent repression of CDKN2A, Chen D, Wang J, Li Y, Xu C, Fanzheng M, Zhang P, Liu L, 2023
• HnRNPR-mediated UPF3B mRNA splicing drives hepatocellular carcinoma metastasis, Wang H, Qian D, Wang J, Liu Y, Luo W, Zhang H, Cheng J, Li H, Wu Y, Li W, Wang J, Yang X, Zhang T, Han D, Wang Q, Zhang CZ, Liu L, 2024